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robotics, have promoted the use of in vitro 
tumor models in high-throughput drug 
screenings.[2,3] High-throughput screens 
for anticancer drugs have been, for a long 
time, limited to 2D culture of tumor cells, 
grown as a monolayer on the bottom of 
a well of a microtiter plate. Compared to 
2D cell cultures, 3D culture systems can 
more faithfully model cell-cell interactions, 
matrix deposition and  tumor microenvi-
ronments, including more physiological 
flow conditions, oxygen and nutrient gra-
dients.[4] Therefore, 3D cultures have 
recently begun to be incorporated into 
high-throughput drug screenings, with the 
aim of better predicting drug efficacy and 
improving the prioritization of candidate 
drugs for further in vivo testing in animals.
Because of the relatively simple, repro-
ducible, amenable to automation and scal-
able culture methods, single-cell type and 
mixed-cell tumor spheroids, known as 
multicellular tumor spheroids (MCTSs), 
are used as 3D models.[5] There exists a 
broad range of natural hydrogels that are 
compatible with microfluidics, and which provide cancer cells 
with mechanical cues and adhesion sites to proliferate and grow 
into MCTSs.[6] With the aid of microfluidics and development of 
more complex 3D tumor models,[7,8] and the large-scale produc-
tion of tumor spheroids in hydrogels, the number of compounds 
that could progress to  in vivo  testing could be restricted, thus 
reducing the number of animals needed for preclinical studies.
Tumor-targeted drug delivery using microparticles and 
liposomes is beneficial compared to conventional drug admin-
istration. This is because encapsulated drug dosages can be 
controlled, healthy tissues can remain unharmed during treat-
ment and drug resistance of cancer cells may be reduced/
prevented.[9,10] Microparticles and liposomes can be tailored 
to specifically target tumor sites using molecular conjugates, 
while avoiding toxic effects.[9]
This review discusses the application of droplet-based micro-
fluidic technologies for the development of accurate in vitro 
tumor models and improved cancer treatment strategies. The 
first part of the review centers around the generation of MCTSs 
in natural hydrogels for a better recapitulation of the in vivo 
tumor microenvironment. The second section is focused on 
microparticle and liposomal production for tumor-targeted drug 
delivery. Emphases is given to microfluidic methodologies for 
the production of these systems, and the potential of compart-
mentalized artificial cells as anticancer drug screening platforms. 
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1. Introduction
The discovery and pre-clinical development of anticancer agents 
often starts with in vitro drug testing before progressing to 
animal studies, to determine, in vivo, the efficacy and safety 
of promising therapeutic candidates.[1] Over the past decades, 
advanced methods for the generation of large chemical libraries 
(i.e., combinatorial chemistry), coupled to affordable laboratory 
Anticancer drug development is a crucial step toward cancer treatment, 
that requires realistic predictions of malignant tissue development and 
sophisticated drug delivery. Tumors often acquire drug resistance and drug 
efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. 
On the other hand, 3D cultures, including multicellular tumor spheroids 
(MCTSs), mimic the in vivo cellular arrangement and provide robust 
platforms for drug testing when grown in hydrogels with characteristics 
similar to the living body. Microparticles and liposomes are considered smart 
drug delivery vehicles, are able to target cancerous tissue, and can release 
entrapped drugs on demand. Microfluidics serve as a high-throughput 
tool for reproducible, flexible, and automated production of droplet-based 
microscale constructs, tailored to the desired final application. In this 
review, it is described how natural hydrogels in combination with droplet 
microfluidics can generate MCTSs, and the use of microfluidics to produce 
tumor targeting microparticles and liposomes. One of the highlights of the 
review documents the use of the bottom-up construction methodologies 
of synthetic biology for the formation of artificial cellular assemblies, which 
may additionally incorporate both target cancer cells and prospective drug 
candidates, as an integrated “droplet incubator” drug assay platform.
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Finally, the future perspectives of droplet-based technologies 
using microfluidics for drug related studies are discussed, where 
artificial cells, constructed from lipid-bound inner compart-
ments, and hydrogels, enable a degree of structural rigidity and 
the additional incorporation of cancer cells and prospective drug 
candidates, as integrated and interactive assemblies (Figure 1).
MCTSs in the presence of extra-cellular matrix (ECM) com-
ponents offer reliable tumor models for drug screening appli-
cations.[11] These components may be in the form of hydrogels 
and can recapitulate tumor complexity and multicellular drug 
resistance.[12] Natural hydrogels include natural polymers and 
ECM components (e.g., polysaccharides, proteins, glycosami-
noglycans) derived from living plants or animals, whereas syn-
thetic hydrogels involve synthetic polymers manufactured by 
chemical methods. In the following subsections of this review, 
focus will be given to natural hydrogels that provide structural 
support and cell adhesion sites, in order to assist MCTS growth, 
by recapitulating the in vivo tumor microenvironments.
1.1. Protein, Polysaccharide, and Hybrid Hydrogels
Natural polymers originate from natural sources, often ren-
dering them highly biocompatible, with gelation conditions that 
can be dependent upon ionic interactions, pH and tempera-
ture.[13] The majority of natural polymers derived from the ECM 
of tissues and organs, includes proteins. Matrigel is a basement 
membrane extracellular (BME) matrix protein extract, which 
can be derived from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma.[14,15] Collagen Type I is one of the major proteins pre-
sent in the ECM of tissues and improves cellular attachment in 
MCTSs studies.[6,16] Fibrin and silk fibroin have also been used 
as hydrogels for tumor related drug studies.[17–20]
A wide range of other natural polymers, such as polysaccha-
rides, are used as hydrogels to replicate the structural characteris-
tics of in vivo tissues. Polysaccharide hydrogels, including alginate, 
chitosan,[21] hyaluronic acid,[22] and agarose cover a range of 
materials that have a demonstrated ability to promote cancer cell 
growth and MCTS formation.[23] Alginate is a polyanionic polymer 
and can be extracted from brown seaweed.[24,25] Chitosan is a 
cationic polyelectrolyte, derived from chitin found in the shells of 
prawns, lobster, shrimp and grabs, by a process known as deacety-
lation.[26,27] The opposite molecular charges of chitosan and algi-
nate permit them to form polyelectrolyte complexes.[28] Literature 
has reported the application of similar polyelectrolyte complexes 
for the study of cancer cells,[29] multicellular tumor growth forma-
tion,[30] as well as drug encapsulation and delivery.[31]
The current interest in hydrogel composites as a platform for 
MCTS formation and drug testing is increasing.[32,33] Collagen 
and collagen derivatives, such as gelatin, have been tested in com-
bination with polysaccharides, to manufacture in vitro 3D tumor 
spheroids (Figure 2a).[34] MCTS formation has been shown to 
be dependent on the ratio of protein to polysaccharide scaffold 
formulation.[33,35] Various articles have reported glioblastoma in 
vitro tumor formation using combination of polysaccharides that 
mimic tumor stiffness accurately.[36,37] The concentration ratio of 
components in hybrid hydrogels used for MCTS systems affects 
porosity and pore interconnectivity which are crucial for suffi-
cient exchange of nutrients and waste products.[38,39]
Natural hydrogels can be produced in a manner to replicate 
in vivo tumor microenvironments and improve the analysis of 
malignant behavior. Table 1 summarizes the advantages and 
disadvantages of protein, polysaccharide, and hybrid hydro-
gels. One of the main disadvantages is the batch-to-batch per-
formance variations.[40,41] Therefore, if batch-to-batch variations 
are controlled by introducing technologies (e.g., microfluidics) 
that provide precise reagent sequence and distribution, repro-
ducible and consistent results using biomimetic hydrogels can 
help minimize the animal models required for tumor studies 
and drug development. This could therefore advance the move-
ment toward replacement, reduction and refinement in animal 
welfare and scientific research.[42]
Figure 1. A schematic diagram describing how in vitro drug screening and delivery systems can be utilised as constituents toward novel microfluidic 
generated drug screening platforms, termed as “droplet incubators”. Multicellular tumor spheroids (MCTSs) in natural hydrogels as in vitro 3D models.
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Figure 2. a) Fluorescence microscopy images of MCTS co-cultures of fibroblasts (green) and cancer cells (red). Tumor invasion occurs only by MCTSs 
surrounded by the collagen-alginate 3D hydrogel. Reproduced with permission.[33] Copyright 2018, Elsevier. b) Microfluidic assisted formation of liver-in-a-
droplet. Microfluidic production of liver-in-a-droplet, where hepatocytes and fibroblasts were encapsulated in the core and shell of the capsule, respectively. 
Reproduced with permission.[62] Copyright 2016, Royal Society of Chemistry. c) A microfluidics device used for production of collagen core and alginate 
shell capsules used for 3D tumor vascularization experiments. 3D vascularized tumors expressed increased drug resistance in the presence of a commonly 
used chemotherapeutic drug, although this resistance reduced when treated with drug carrying nanoparticles. Reproduced with permission.[63] Copyright 
2017, American Chemical Society. d) The rationale of combining microfluidics, hydrogels and cancer cell encapsulation in order to produce high throughput 
personalized drug treatments. Reproduced with permission.[46] Copyright 2019, John Wiley and Sons.[64] Copyright 2020, American Chemical Society.
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1.2. Cell Encapsulation Using Droplet-Based Microfluidics
Multiphase droplet-based microfluidics is a method extensively 
studied for cell encapsulation,[43] as it is governed by the auto-
mated formation of droplets.[44] To achieve droplet formation 
using microfluidics, immiscible phases (e.g., water, oil) and 
geometries, such as a T-junction, flow-focusing junction and 
co-flow junctions, are frequently employed.[45,46] Droplet for-
mation is governed by shear stresses and interfacial tension 
between the immiscible fluids and the channel walls, while the 
size of the droplets is determined by the flow rate ratio (FRR) 
and the size of the microfluidic channels.[47] Single cell and 
multiple cell encapsulation protocols have been established 
using microfluidics and hydrogels, in order to investigate single 
cell behavior within a designated ECM, and to study cell-cell 
and cell-ECM interactions, respectively.[48,49] The application of 
microfluidics allows for experimental flexibility and agility as 
well as targeted and minimized resource consumption, which 
is of considerable benefit to cancer research, since the costs of 
drugs and reagents demand high precision.[50]
Entrapped cells in a confined environment, such as within 
hydrogel beads produced using microfluidic technology, can be 
analyzed on or off-chip.[51] Cell encapsulation within a micro-
fluidic device can be achieved, usually, by combining droplet 
forming geometries and liquid polymers (as the dispersed 
phase), which, under crosslinking, form a biological scaffold 
for the cells to grow into 3D spheroids.[45,52] Relatively simple 
T-junction microfluidic geometries have been used to enable 
cell encapsulation and cell growth assessment in the pres-
ence of hydrogel used as the ECM.[53] However, more complex 
flow-focusing junction geometries offer platforms that enable 
more sophisticated cell encapsulation procedures, control 
over gelation and protection of cells from potential harmful 
environments.[54–56] Moreover, the density and viscosity of rea-
gents flowing through microfluidic channels are important 
parameters that influence cell encapsulation. With appropriate 
microfluidic designs, the manipulation of these properties can 
enable different encapsulation structures, such as core-shell 
hydrogel spatial arrangements.In addition to manipulating flow 
rates and reagents, microfluidics can integrate more complex 
fluidic circuitry and multi-functionalism that is required for 
high throughput technologies in large scale cancer studies.[7,50] 
Finally, the combination of hydrogels and droplet microfluidics, 
offer the possibility to produce tumor tissue forming droplets 
and proceed to complex on or off chip drug assays, involving 
multiple cell types.
1.3. Cancer Spheroid Analysis and the Application  
of Droplet-Based Microfluidics
Proteins,[57] polysaccharides and hybrid hydrogels,[58–60] 
have been produced using droplet microfluidic technolo-
gies for MCTS culture systems and drug evaluation. Flow 
focusing microfluidic platforms are capable to create various 
architectures, including core-shell profiles (Figure  2b).[61,62] 
Agarwal et al. used droplet-based microfluidics to form MCF-7 
microtumors in a collagen core surrounded by an alginate 
shell (Figure  2c).[63] These microcapsules were formed at 
the junction of five microfluidic channels and when micro-
tumors developed, they assessed anticancer drugs based on 
3D vascularization experiments. Droplet-based microfluidics, 
used for the formation of cell-laden, hydrogel constructs, can 
enable diverse architectural formats, precision control over 
the manipulation of encapsulating materials and the process 
sequencing. This can enable multiple cell type co-cultures in 
predefined microenvironments, that better simulate in vivo 
tissue complexity, thus making possible the development of 
high throughput platforms for drug treatments tailored to 
patients (Figure 2d).[64]
Table 1. Advantages and disadvantages of protein, polysaccharide and hybrid hydrogels.
Hydrogel Advantages Disadvantages Ref.
Proteins Natural origin




Ideal for cell dynamics and migration











Structural support of cells
Mild gelation conditions
Batch-to-batch variations
Lack of cell adhesive ligands
Low mechanical properties
Might develop necrotic cores
[24,27,28,40,41]
Hybrids Improve mechanical properties
Improved pore interconnectivity
Cell adhesion sites available
Tunable characteristics
Realistic recapitulation of tissue stiffness
Good pore interconnectivity
Batch-to-batch variationsCrosslinking mechanisms 
may be difficult to achieve
May be difficult to tune physicochemical 
characteristics
[32–34,36,39]
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2. Drug Delivery Systems and Droplet-Based 
Technology
Local delivery of therapeutic drugs can provide safe and effec-
tive ways for combating pathologies, such as cancer. Micro-
particles and liposomes can encapsulate drugs and deliver 
conjugates to the diseased tissue site, following passive and/
or active release.[65–67] The production of liposomes using tra-
ditional methods, include thin-film hydration and ethanol 
injection,[68,69] and for microparticle production, membrane 
emulsification, precipitation and emulsion polymerization.[70] 
Compared to conventional fabrication methods of micro-
particles and liposomes, microfluidic platforms offer ben-
efits including reproducibility, control over size, precision 
processing and other as shown in Table 2.
2.1. Microparticles as Drug Carriers
2.1.1. Control of Content Release from Microparticles
Microparticles can be used to encapsulate anticancer drugs[75] 
and other molecules such as antibodies,[76] peptides,[77] 
enzymes,[72] proteins,[78] growth factors,[79] indicators,[80] and 
phages for different biomedical applications.[81] These encapsu-
lants can be released from the microparticles to the surround-
ings in either a passive or an active mechanism, depending 
upon the matrix material and the particle structure. The 
passive release mechanism is achieved through the degra-
dation/hydrolysis of the matrix or the protective shell.[82] Time-
dependent and sequential release of drugs can be realised by 
the design of multiple shells and multi-core microparticle 
structures.[83,84] On the other hand, active release relies upon 
the microparticles being constructed from responsive mate-
rials.[85] Such materials actuate a shape deformation that trig-
gers a burst, or sustained release of encapsulants, responding 
to environmental variations and/or external stimuli.[86] Stimuli-
responsive microparticles can be fabricated for the selective 
release of drugs, triggered by electrical fields,[87] magnetic fields 
(Figure  3a),[88] heating,[89] ultrasound,[90] infrared red light,[91] 
pH change,[92] redox,[93] or the presence of enzymes.[94] Micro-
particles can also be engineered to have multifunctionalities, 
such as sensing, directionality and mobility, which enables the 
delivery of encapsulants to the target area.[95–97] 3.1.2. Matrix 
materials and structures of microfluidic formed microparticles
Using microfluidics, anticancer drug-loaded microparti-
cles can be prepared from a range of biocompatible materials, 
including lipid-coated droplets,[98] polymers,[99] hydrogels,[100] 
and metals.[101] Among these, poly(lactic-co-glycolic acid) 
(PLGA), is a well-researched polymeric material approved by 
the FDA as a safety drug vehicle.[71,75,102] Biopolymers, such 
as proteins, gelatin, chitosan and alginate, are used to pro-
duce drug-loaded microparticles using microfluidics to study 
cell responses, both in vitro and in vivo.[103–106] Other stimuli-
responsive microparticles produced using microfluidics include 
PEG,[107] polylactide,[108] graphene oxide,[109] polyurea,[110] 
polyester,[93] poly(N-vinylcaprolactam),[89] and fatty alcohol 
(Figure 3b),[91] tailored with properties for various biomedical 
and drug delivery applications.
The morphologies of microparticles formed within micro-
fluidic channel systems can be classified according to three 
categories, including i) spherical microbeads,[111] ii) core-shell 
shaped microcapsules,[86] and iii) irregular shaped microparti-
cles (Figure 3c). Irregular shaped microparticles, such as fibers, 
disks or anisotropic shapes, can be produced by alterations to 
the geometry constraints of fluidic channels, on emulsion drop-
lets during their formation and consolidation processes.[89,112] 
Janus droplets have two or more distinct physical surface 
properties, and can be prepared either from the conjuga-
tion of several dispersed phases without mixing, or, from the 
phase separation of a droplet preloaded with mixed reagents 
(Figure 3d).[113] These amphiphilic microparticles harness polar-
ization from their structures, and can enable the staged release 
of drugs. Moreover, microfluidics can control the surface prop-
erties and porosity of microparticles, dependent upon the emul-
sion systems and the inflow parameters.[114,115] Such properties 
not only influence the release kinetics of the encapsulants from 
the microcapsules,[116] but also affects the adhesion of micropar-
ticles to the in vivo environment.[117]
2.1.2. Microfluidic Production of Microparticles for Drug Delivery 
and Screening
Microfluidics has been utilised for anticancer medicine devel-
opment in the last few decades.[118,119] Microfluidic devices 
can be fabricated by subtractive micromachining processes, 
including reactive ion etching (RIE) on silicon,[120] polymers 
and glasses, hot-embossing,[121] and injection molding of poly-
mers,[122] laser micromachining,[123] and surface micromilling 
of metals, glasses, polymers and silicon,[124] as well as more 
recently, additive manufacturing processes.[125] In microfluidics, 
consistent droplet formation is essentially determined by con-
tinuous and stable fluid injection.[126] which highly depends 
on the pumping system mechanisms.[127–130] With more recent 
progress in nanofluids, nano-scale droplet forming junctions 
can be integrated within conventional microfluidic circuits to 
produce monodisperse nanoparticles for intracellular drug 
Table 2. Comparison of conventional and microfluidic production 




















Flexibility in experimental 
design
Fabrication and microfluidic 
skills needed
Low control over particle 
shape
Low final concentrations in 
end product
[71–74]
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delivery and preclinical drug screening.[131] The employment 
of droplet microfluidics for microparticle formation, also ena-
bles the integration with other drug delivery platforms, such 
as microneedles,[132] acoustics,[133] electrostatic atomization,[134] 
electrospinning,[135] magnetic-assisted layer-by-layer coating to 
prepare and deliver drug loaded microparticles and scaffolds.[136]
With the development of new materials and microfluidic capa-
bilities, sophisticated microparticles can be constructed from 
hybrid materials with hierarchical structures, that contributes to 
a programmable drug uptake, encapsulation and selective release 
process.[137] Microfluidic processing methodologies are available 
for the mass fabrication of drug-loaded microparticles, using 
parallel droplet forming arrays and multiplexed drug assays.[138] 
These efforts are one step forward to manufacture smart drug 
microcarriers that harness on-demand active targeting, and 
enable quantity-controlled release of drugs for cancer therapy.
2.2. Liposomes as Drug Carriers
2.2.1. Stimuli Responsive Liposomes
Artificial vesicles, usually termed liposomes, of both uni- and 
multi-lamellar phospholipid bilayer structures around an 
aqueous core, can range in size from ∼30nm to 100s of µm.[139] 
Such liposomal structures serve as very effective, “designer” drug 
delivery vehicles, due to their unique characteristics, including 
structural fluidity, biocompatibility, low toxicity and non-immu-
nogenicity making them ideal platforms for hydrophilic and 
hydrophobic drug encapsulation.[140,141] Drug-loaded liposomes 
can be injected intravenously into animal models for drug 
related studies and their functionalisation may be beneficial for 
precision pharmacokinetics, while preventing adverse effects.[142] 
Stealth-liposomes (S-liposomes), allow longer circulation times 
in the blood stream due to reduced uptake by reticuloendothelial 
system (RES),[143,144] as PEG makes liposomes more hydrophilic 
and prevent opsonins from adhering.[145]
A broadly used example of stimuli-responsive liposomes are 
thermo-sensitive liposomes (TSLs), which rely upon the phase 
transition of phospholipids, from gel to liquid.[146,147] Having a 
phase transition above physiological temperatures, liposomes 
become leaky and the contents leak out.[148] The addition of 
lysolipids and polymers into liposomes reduces the transi-
tion temperature to that which is much closer to physiological 
temperatures.[149–151]
Some of the most known drug release external stimuli are 
summarized in Table 3. Ultrasound is a widely available diag-
nostic imaging tool in clinical settings and can also serve 
as ideal means for triggering the selective release of drugs. 
Broadly, the application of ultrasound for liposomal drug 
release relies on i) thermally triggered release and, ii) non-
thermal membrane disruption.[152] Other stimuli include high 
frequency and low frequency magnetic fields,[153–155] NIR,[156–158] 
and UV radiation.[159,160]
Various stimuli-responsive liposome constructs can release 
encapsulated content under external effects, whether they are 
composed of susceptible lipids, polymers, or other agents and 
particles. It is of considerable importance that biocompatible, 
Figure 3. a) Magnetically responsive drug-laden chitosan capsules fabricated using microfluidics. The chitosan droplets are loaded with superparamag-
netic iron oxide nanoparticles (SPIO NPs) and chemotherapeutic drug, vinblastine (VBL), which is released by a pulsatile magnetic field. Reproduced 
with permission.[88] Copyright 2019, MDPI. b) Droplet microfluidics fabricated near-infrared (NIR) responsive 1-tetradecanol microparticles, carrying 
doxorubicin (DOX)/ IR780 (photothermal agent). DOX release is achieved under NIR light pulses. Reproduced with permission.[91] Copyright 2019, Else-
vier. c) Graphic diagrams and microscopy images of possible polymer microparticles fabricated using microfluidics. Reproduced with permission.[106] 
Copyright 2019, John Wiley and Sons. d) Lipid-polymer Janus microparticles fabricated using microfluidics and solvent evaporation. Different structures 
achieved by altering the concentrations of the phases. a) Janus, b) Janus-patchy, c) Triple, d) Quadruple, e,f) Core-shell and sustained paclitaxel release 
from Janus microparticles. Reproduced with permission.[113] Copyright 2019, Elsevier.
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drug-laden, stimuli-responsive liposomes, function appropri-
ately, whilst simultaneously, ensuring that external stimuli 
do not induce undesired effects upon the host tissue. Drug 
delivery using liposomes can be tailored specifically to tumor 
types, and the physicochemical characteristics of the tumor 
microenvironment can be taken into advantage to trigger drug 
release by other internal and passive means.
2.2.2. Tumor Targeted Liposomes
Tumor targeted liposomes follow either passive or active accu-
mulation at cancerous tissues. The Enhanced Permeability 
and Retention (EPR) effect relates to drug nanocarriers, such 
as liposomes and microparticles, that passively meet and 
penetrate damaged vasculature and reach the location of the 
tumor.[163] In addition to the passive targeting of tumors by the 
PEGylation of liposomes, the active targeting of liposomes has 
demonstrated the specific accumulation of liposomes at tumor 
sites (Figure 4a).[9] Antibodies,[164] peptides,[165] ssDNA,[67] have 
all been used as ligands on liposomes, which are recognized 
by specific tumor, or endothelium receptors. It is believed that 
these methods for targeted drug delivery using Tumor Targeted 
Liposomes (TTLs) can resolve issues associated with safety and 
efficacy in cancer theranostics, while also reducing the suf-
fering of pre-clinical animal models.[166]
The tumor microenvironment differs from normal, healthy 
tissues, due to its altered characteristics, such as acidic pH, 
higher temperatures and hypoxia.[167] Several researchers 
developed drug loaded ligand carrying liposomes that can 
endogenously release drug upon contact with such character-
istics.[167–169] Overexpressed cell surface receptors in tumors, 
are folate receptors,[170] transferrin,[171] epidermal growth 
factor receptors (EGFR),[172] fibroblast growth factor receptors 
(FGFR),[173] CD44 receptors (Figure  4b),[174,175] and the respec-
tive ligands grafted to liposomes can initiate endocytosis and 
drug release upon contact.[176] Enzyme levels are also altered 
in the tumor microenvironment, and these have been utilised 
as an internal stimulus for drug release from liposomes, via 
liposome- tumor cell fusion.[177,178] Whilst the pH, tempera-
ture, and enzyme alterations at the tumor microenvironment 
act as initiators for the drug release from liposomes, internally 
induced release only, might not circumvent drug resistance.[179]
Externally induced drug release from liposomes includes 
light and heat producing methods, known as photodynamic 
therapy (PDT).[180] PDT in combination with magnetic particles 
presents imaging applications.[181] Tumor angiogenesis visuali-
zation using MRI imaging was achieved though the passive or 
active delivery of magnetic liposomes.[181,182] Li  et  al. also pro-
posed a combined approach (PDT, MRI imaging and immu-
notherapy), using IR dye, MRI contrast agent, and anti-EGFR 
antibody on liposomes for targeting, treating and imaging colo-
rectal tumors.[183] Figure 4c summarizes the possible modifica-
tions to produce functional and stimuli responsive liposomes, 
in order to encapsulate and deliver drugs effectively.[180]
2.2.3. Microfluidics for Liposome Production and Drug 
Encapsulation
Liposome formation is governed by the self-assembling nature 
of lipids, due to their hydrophobic and hydrophilic parts, 
leading to the formation of vesicles. Microfluidic technologies 
have been utilized for liposome synthesis, by controlling the 
interface of flowing components, such as Microfluidic Hydro-
dynamic Focusing (MHF) devices.[184] The process by which 
the liposomes self-assemble in this MHF device is based on 
the reciprocal diffusion of alcohol/lipid and water at the down-
stream interface formed within the central channel of the chip, 
as shown in (Figure 5a).[185] Following studies determined the 
parameters of MHF devices that influence the diameter, disper-
sity and production rate of liposomes. Such parameters include 
the width of the alcohol stream,[186] downstream turbulence,[187] 
flow rate ratio,[188] and width to height ratio of the microfluidic 
channels.[189,190] Increasing the number of diffusion interfaces 
within an MHF device increases the productivity of controlled 
sized liposomes, due to faster lipid hydration, as demonstrated 
using a double hydrodynamic focusing (DHF) microfluidic 
Table 3. External stimuli and corresponding mechanism of drug release from liposomes.
External stimulus Mechanism of release Ref.
Ultrasound
High intensity focused ultrasound (HIFU) or  
Low frequency Ultrasound
• Ultrasonic beam focused at a focal point
• Heating of diseased area administered with drug encapsulated liposomes




High Frequency Magnetic fields or Low frequency 
alternating current (AC) magnetic fields
• Requires thermally responsive liposomes
• Hyperthermia due to heating above the gel-to-liquid transition temperature
• Magneto-mechanical actuation of bilayer
• Low frequency magnetic fields are considered safer
[153–155]
Near Infrared Light • Photosensitive agent loaded liposomes.
• Heating of particles encapsulated in liposomes upon radiation  
(magnetic and gold nanoparticles)
• Heating effects causes microcavity and bilayer disruption
• Other mechanism is cell penetrating peptide activation upon NIR light exposure
[156–158]
Ultraviolet Light • UV light sensitive agents grafted onto liposomes
• Activation of photosensitive agent upon exposure
• Polymerization reactions between photosensitive lipid molecules
[159,160]
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device.[191] Cell-sized vesicles have been also produced by double 
emulsions and organic solvent removal (Figure 5b).[192,193]
Other microfluidic designs, apart from MHF devices, include 
the staggered herringbone micromixer (SHM), shown in 
Figure  5c.[194] Microfluidic devices with integrated SHMs pro-
duce liposomes following chaotic advection and have been used 
for, the formation of stable SUVs encapsulating low water-soluble 
drugs,[195,196] the production of liposomes for anticancer drug 
studies,[197] as well as for the production of commercially available 
liposomes.[198] Microfluidic geometries can host a sequence of 
reactions for liposome stabilization and control over drug encap-
sulation efficacy.[199,200] Microfluidic production of drug-loaded 
liposomes using organic solvents require minimal post treat-
ment to remove such solvents that influence the final product 
(Figure 5d).[201,202] Drug loaded liposomes produced using either 
MHF or SHM devices, have reached tumor sites due to their very 
narrow size and sufficient encapsulation efficacy.[191,200,202] Mass 
production of these artificial vesicles by microfluidics is of great 
benefit to the pharmaceutical industry to produce amphipathic 
chemotherapeutic drugs, using considerably small volumes.
3. Artificial Cells as Programmable Drug Delivery 
Platforms
In recent years, artificial cells have been developed based 
on compartmentalized particles and vesicles that have been 
applied to drug development and therapies.[203,204] One key aim 
of artificial cell research is to impart new functionalities upon 
either engineered natural cells through a top-down approach, 
or through bottom-up constructed protocells from non-living 
elements, with de novo structure.[205] Bottom-up constructed 
artificial cells, also referred to as cell mimics,[203,206] may be 
imparted with one or more cell-like features and behaviors, 
through the organization of biochemical reactions and the 
control of chemically-mediated information, within internal 
compartmentalized structures, such as vesicles.[207,208] These 
structures can be formed by the self-organization of molecules 
within an emulsion system, forming membrane-bounded 
droplets with lipids, amphiphilic polymers and nanoparti-
cles,[209] as well as, membrane-free systems from coacervation 
(Figure 6a).[210,211]
Figure 4. a) Representation of intravenous delivery of encapsulated drug in nanocarriers. (Top) Passive targeting of liposomal nanocarriers through the 
EPR effect, (Bottom) Ligand carrying liposomes for active tumor targeting. Reproduced with permission.[9] Copyright 2019, John Wiley and Sons. b) An 
example of drug carrying tumor targeting liposome through a hyaluronic acid conjugate recognized by CD44 receptor. The liposome is endocytosed 
and acidic pH within a transformed cell causes the release of the docetaxel anticancer drug. Reproduced with permission.[175] Copyright 2018, Elsevier. 
c) Presentation of multiple approaches to design stimuli responsive liposomes, while incorporating targeting ligands to achieve selective drug release. 
Reproduced with permission.[180] Copyright 2017, John Wiley and Sons.
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Figure 5. a) MHF device, with alcohol/lipids and water as inlets. Reciprocal diffusion at the interface of the two phases causes lipid hydration and vesicle 
formation, due to the self-assembling nature of lipids. Reproduced with permission.[185] Copyright 2021, Royal Society of Chemistry. b) Double emulsion of 
water in octanol/lipid and automated octanol extraction leads to formation of liposomes. Reproduced with permission.[193] Copyright 2016, Nature Commu-
nications. c) Microfluidic device that combines a Y-junction and SHM for liposome generation. Reproduced with permission.[194]Copyright 2019, Elsevier. 
d) Microfluidic device for liposome formation followed by post treatment using buffer for organic solvent removal. This microfluidic integrated post treating 
step avoids fusion of liposomes and does not affect encapsulation efficacy. Reproduced with permission.[202] Copyright 2020, American Chemical Society.
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Figure 6. a) Guest-host protocell construct for activation of synergistic or antagonistic behaviors. Glucose oxidase (GOx) containing proteinosome (guest 
protocell), trapped in a fatty acid micelle coacervate (host protocell). Depending on the glucose concentration of the surroundings, pathway 1 (synergistic) 
or 2 (antagonistic) is initiated. Low glucose concentration causes the coacervate to become fluorescent and high glucose concentration decreases pH and 
induces the formation of fatty acid vesicles. Reproduced with permission.[211] Copyright 2018, Springer Nature. b) Schematic illustration for the formation 
of DIBs, multicore artificial cell constructs produced by droplet microfluidics and one or multiple DIBs and aqueous solutions encapsulated in a hydrogel 
capsule. Reproduced with permission.[213] Copyright 2016, John Wiley and Sons. c) Highly compartmentalized capsules produced using novel bat-wing junc-
tion, a–o) 2–15 water droplets encapsulated within solid semi-permeable capsules, p–r) Different water droplets trapped in solid TMPTA solid capsules, s,t) 
encapsulated DIB networks in TMPTA/water/squalene. Reproduced with permission.[240] Copyright 2017, Royal Society of Chemistry. d) Enzymatic reaction 
pathway in a natural eukaryotic cell and cell inspired hollow hydrogels encapsulating inverse opal particles with immobilized enzymes fabricated using 
microfluidics. Reproduced with permission.[218] Copyright 2018, AAAS. e) Encapsulation of DIBs in alginate shells using non-planar droplet microfluidic 
device. The outermost shell contains components such as magnetic particles, which offer mobility to the artificial cell construct in the presence of a magnet. 
Reproduced with permission.[127]. Copyright 2019, John Wiley and Sons. f) Vesicle-cell engineered hybrid, where hydrolysis of lactose to glucose within the 
hybrid causes a chemical reaction that produces fluorescence. Reproduced with permission.[230] Copyright 2018, Springer Nature.
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Several vesicle-based protocell models have been designed, 
including liposomes, polymersomes, proteasomes, colloi-
dosomes, and coacervates.[212] Compartmentalized structures, 
including vesicles and droplet interface bilayers (DIBs) can be 
shaped within such models, as a counterpart to natural cel-
lular organelles, and devised to orchestrate local chemical gra-
dients and reactions (Figure 6b).[213,214] In comparison to other 
fabrication methods, droplet microfluidics has the advantages 
of precision control on the compartment size, structure and 
encapsulant (Figure  6c).[215,216] Thereby, the precision control 
afforded by the use of microfluidics, provides a versatile plat-
form to develop new functionalities, such as membrane prop-
erties,[217] sequential biochemical reactions (Figure  6d),[218] 
cell-free gene expression,[219] and protein synthesis.[220] In 
addition, an increasing number of different functionalities 
may be integrated within artificial cells as a simple program, 
involving sensing,[221] predation,[222] self-sustainability,[223] dif-
ferentiation,[224] and mobility (Figure 6e).[127] This enables the 
exploration of the emergent, collective behavior of artificial 
cells to direct higher level activities, such as artificial cell-
based information integration and processing and chemical 
delivery decision making.[225]
With recent progress, artificial cells have been applied to 
various biotechnologies and drug development processes. 
Several works demonstrated the feasibility of employing 
artificial cells as smart carriers for anticancer drug delivery 
and screening applications.[204,226,227] Encapsulated drug 
molecules may be released through certain drug metabolic 
pathways, while self-reporting mechanisms may act as feed-
back. Such characteristics can be fundamentally enabled by 
the ability to control chemical information exchange during 
the interactions between artificial cells and living cells 
(Figure 6f ). For example, artificial cells can be used to actuate 
or suppress the sensory pathways of microorganisms.[228] To 
enable such efficient interactions, artificial cells and living 
cells, need to be appropriately integrated within the cell 
signaling range.[229] This can be achieved by the encapsula-
tion of living cells within an artificial cell chassis,[230] or by 
spatial confinement using acoustic standing waves or fluidic 
structures.[231] Living cells can be also bounded to artificial 
membranes via DNA tags.[232] With the increasing preci-
sion of bioengineering, complex artificial cell colonies or 
prototissues can be constructed to facilitate artificial-natural 
cell interactions, constructed through step-by-step emulsi-
fications, or via droplet-by-droplet assembly with manual 
deposition, or 3D-printing methods.[233] These prototissue 
models can be programmed to have precise and functional 
geometries,[234] and be responsive to external stimuli,[235–238] 
to trigger sequential biochemical reactions. Recently, pioneer 
studies demonstrate that prototissue models can be utilised 
to explore the metabolic pathway of natural cells and the 
development processes of organs.[212,239] With the develop-
ment of artificial cellular constructs using bottom-up or top-
down approaches, crucial information regarding cell growth, 
communication and interaction can be accumulated. Lastly, 
the researched literature indicates that artificial cells and 
their assembly could be a powerful platform to design novel 
drug metabolic pathways for programmable drug targeting 
and delivery.
4. Future Perspectives
We have shown that recent advances in precision droplet micro-
fluidic technologies, is a key future enabler for both in vitro 
MCTSs formation, and anticancer drug delivery. Current anti-
cancer drug screening employs a stepwise process, including 
(1) the development of cancer spheroid and organoid from 
individual cells, (2) the addition of candidate drugs with time 
points and concentration controls, and (3) the post processing 
and analyzing of samples. These discrete procedures normally 
require several sample transfers, continual manual handling, 
and the experimental results typically depend upon specific 
protocols and laboratory environments with inevitable opera-
tional errors. A future vision to enable a step change in anti-
cancer drug development, involves the conjugation of both the 
cancer cells and the drug vehicle encapsulations (e.g., vesicles, 
microgels, polymeric capsules), within the same precision com-
partmentalized entity. Such a concept would comprise a novel 
microfluidically formed device, termed here as a “droplet incu-
bator”, as a new platform for drug screening. The droplet incu-
bator could incorporate natural cells, pharmaceuticals and other 
components, within separated intra-capsule compartments, and 
enable the in vitro MCTS development and the interaction of 
micro tumors and drug candidates, in the same physical (incu-
bator) construct, in a temporally-programmed manner. The 
materials and the formation profiles of droplet incubators could 
provide the programmability to allow high throughput experi-
ment, with parametric controls on the cell populations, drug 
quantification, and drug release and penetration. A schematic 
of such a droplet incubator is illustrated in Figure 7. Tumor cell 
encapsulation and liposomal/microparticle/artificial cell, drug 
delivery vehicles, are combined within one precision-assembled 
capsule, produced using multiphase droplet microfluidics. 
Such constructs would allow MCTS formation in a tissue mim-
icking environment, while drug release could be initiated in a 
programmable approach, involving the droplet structures, (bio)
material properties, and external stimuli. The spatial arrange-
ment of the drug carriers and tumor cells could be controlled 
with precision microfluidics, leading to various functional 
configurations.
The repeatable precision manipulation of small liquid 
quantities, through the use of multiphase microfluidics, is 
now enabling the physical formation of such programmable 
droplet incubators, incorporating spheroids and organoids, 
for advanced drug evaluation studies. Such droplet incuba-
tors can be incorporated within numerical models.[241,242] As 
an example, a numerical chemical compiler application is 
being developed, to enable the computer-assisted design of 
microfluidics for the construction of artificial cells and droplet 
incubators.[243,244]
5. Conclusion
Pathologies like cancer require patient specific treatments, 
due to the heterogenous genetic and epi-genetic alterations 
across individuals, which cause limitations in the screening 
of anticancer drugs using conventional 2D cell cultures. 
To overcome some of these limitations, tumor growth and 
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drug resistance can be modelled in vitro using 3D models, 
including MCTSs. Protein and polysaccharide polymers 
provide a wide range of materials that can be used to grow 
MCTSs in vitro, predict migration and angiogenesis, and pro-
gram drug therapies to prevent aggressive tumor behavior. 
However, manual handling of these natural hydrogels may 
give rise to concentration variations, slower experimental 
procedures and suffer from human errors. Micro-MCTSs 
grown in hydrogels that simulate animal tumor tissues can 
be produced using droplet microfluidics. Cell-laden hydrogels 
using droplet forming geometries within a microfluidic device 
can be fabricated to obtain uniform, core-shell, or multilayer 
structures. Controlled drug delivery to targeted tumor sites 
using microparticles and liposomes is an important advance-
ment for avoiding adverse effects and reducing drug resist-
ance. Targeting ligands for specific tumor cell receptors can 
be linked to microparticles and liposomes, and passively or 
actively accumulate at the tumor location and release the anti-
cancer drug through internal or external stimuli. Microfluidic 
techniques provide the tools for the precision encapsulation of 
multiple drugs, molecules, and cells, and is enabling increas-
ingly programmed reactions within a single physical construct 
(i.e., droplet incubator) for both tumor drug screening and 
targeted drug delivery.
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Figure 7. Schematic illustration of the stages required to perform anticancer drug screening using droplet incubators. a) A representation of a droplet 
incubator. The outer hydrogel shell of the droplet incubator hosts cancer cells and over incubation develop tumor spheres. The core is divided into 
three sections suggesting drug encapsulation and release systems. DIBs section proposes a cascade of reactions (A→E), that involves lipid bilayers 
and protein pores aiming the release of certain drug(s), to the shell. Another pie section describes possible smart nanocarriers (tumor targeting 
liposomes and microparticles) for the release of chemotherapeutic drugs under the influence of internal or external effects. Drug screening is possible 
by incorporating programmability within the context of artificial cells in the presence of tumorspheres. b) Hydrophilic Drug A and Drug B dilutions 
are performed within a microfluidic device. [Chip (shown) fabricated by 3D printing (unpublished data by the authors) for Worldcare Technologies Inc, 
using the design from,[245,246])] c) The candidate drug(s) flow into a device with droplet forming junctions which can generate triple emulsions (i.e., 
droplet incubator) at the outlet. d) Droplet incubators collected into a 24-well plate for further analysis. Each well may host a single droplet incubator 
to generate a concentration gradient and drug ratio array, depending on the dilutions from the microfluidic chip in b).
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